Physician profile
Mary Crowell
NPI 1003854365
$4,787.95
in general payments reported to CMS, 2019-2025
39 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,312 · 2020: $523 · 2021: $105 · 2022: $67.72 · 2023: $394 · 2024: $1,075 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $780.71 | 2019-2025 | Evenity, Prolia, Tavneos |
| Abbott Laboratories | $567.25 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $470.36 | 2019-2025 | Mounjaro, Zepbound, Taltz |
| Novo Nordisk INC | $310.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.29 | 2019-2025 | Jardiance, Cyltezo, Ofev |
| Astrazeneca Pharmaceuticals LP | $217.28 | 2019-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $182.81 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $172.30 | 2023-2025 | Benlysta |
| Ucb, INC. | $170.78 | 2024-2025 | Bimzelx, Cimzia |
| Xeris Pharmaceuticals, INC. | $153.44 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $124.01 | 2023-2025 | Minimed 780g |
| Abbvie INC. | $122.40 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $118.62 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $110.72 | 2019-2023 | |
| Fresenius Kabi USA, LLC | $107.29 | 2024-2025 | Idacio, Tyenne |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Crowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.